Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial

The Lancet Oncology

Volumn 13, Issue 6, 2012, Pages 579-588

  Hofheinz, Ralf Dieter ^a   Wenz, Frederik ^a   Post, Stefan ^a   Matzdorff, Axel ^b   Laechelt, Stephan ^c   Hartmann, Jörg T ^d   Müller, Lothar ^e   Link, Hartmut ^f   Moehler, Markus ^g   Kettner, Erika ^h   Fritz, Elisabeth ⁱ   Hieber, Udo ^j   Lindemann, Hans Walter ^k   Grunewald, Martina ^l   Kremers, Stephan ^m   Constantin, Christian ⁿ   Hipp, Matthias ^o   Hartung, Gernot ^p   Gencer, Deniz ^a   Kienle, Peter ^a   Burkholder, Iris ^q   Hochhaus, Andreas ^r   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Clinic for Hematology and Oncology   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e Christian Albrechts University ^*  (Germany)

^f Westpfalz Hospital   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h Hospital Magdeburg   (Germany)

ⁱ Clinic for Internal Medicine Stiftungsklinikum Mittelrhein   (Germany)

^j Oncology Practice   (Germany)

^k Katholisches Krankenhaus   (Germany)

^l Hospital Aschersleben Staßfurt   (Germany)

^m Caritas Hospital   (Germany)

ⁿ LIPPE HOSPITAL   (Germany)

^o UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^p Oncology Practice   (Germany)

^q GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^r JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL;

ABDOMINAL PAIN; ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GERMANY; HAND FOOT SYNDROME; HUMAN; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SIDE EFFECT; STOMATITIS; THROMBOCYTE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CROSS-OVER STUDIES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861547511     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70116-X     Document Type: Article

References (23)

1. Martling A, Holm T, Rutqvist LE, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg 2005, 92:225-229.
2. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-820.
3. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011, 12:575-582.
4. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
5. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
7. Schmiegel W, Reinacher-Schick A, Arnold D Update S3-guideline colorectal cancer 2008. Z Gastroenterol 2008, 46:799-840. (in German).
8. Tepper J, O'Connell MJ, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114. J Clin Oncol 2002, 20:1744-1750.
9. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331:502-507.
10. Kalofonos HP, Bamias A, Koutras A, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing irinotecan, 5FU and leucovorin to 5FU and leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 2008, 44:1693-1700.
11. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
12. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
13. Glynne-Jones R, Dunst J, Sebag-Montefiore D, et al. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. Ann Oncol 2006, 17:361-371.
14. Tunes da Silva G, Logan BR, Klein JP Methods for equivalence and non-inferiority testing. Biol Blood Marrow Transplant 2009, 15(suppl 1):120-127.
15. Machin D, Gardner MJ Calculating confidence intervals for survival time analyses. BMJ 1988, 296:1369-1371.
16. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5 fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2011, published online Sept 6. 10.1093/annonc/mdr366.
17. Sanghera P, Wong DW, McConkey CC, Geh JI, Hartley A Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol) 2008, 20:176-183.
18. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 3503.
19. Yothers G, Ganz PA, Lopa SH, Ko CY, Wickerham DL, Wolmark N Patient-reported outcomes (PROs) comparison of 5 FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: results of NSABP R-04. Proc Am Soc Clin Oncol 2012, 30(suppl 4). abstr 391.
20. Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer 2011, 105:206-211.
21. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28:1638-1644.
22. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29:2773-2780.
23. Roedel C, Becker H, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. Proc Am Soc Clin Oncol 2011, 29(suppl):LBA3505.